BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+4.62%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$115M
AUM Growth
+$115M
(-6.3%)
Cap. Flow
-$6.8M
Cap. Flow
% of AUM
-5.91%
Top 10 Holdings %
Top 10 Hldgs %
66.12%
Holding
72
New
4
Increased
20
Reduced
12
Closed
4
Top Buys
| 1 |
uniQure
QURE
|
$728K |
| 2 |
OrthoPediatrics
KIDS
|
$493K |
| 3 |
Solid Biosciences
SLDB
|
$476K |
| 4 |
Xenon Pharmaceuticals
XENE
|
$369K |
| 5 |
Prothena Corp
PRTA
|
$351K |
Top Sells
| 1 |
Outset Medical
OM
|
$3.81M |
| 2 |
Karyopharm Therapeutics
KPTI
|
$1.47M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$1.25M |
| 4 |
Corcept Therapeutics
CORT
|
$914K |
| 5 |
United Therapeutics
UTHR
|
$771K |
Sector Composition
| 1 | Healthcare | 96.33% |
| 2 | Energy | 3.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Xenon Pharmaceuticals
XENE
$2.98B
| $705K | 0.61% | 21,000 +11,000 | +110% | +$369K |
|
27
Axsome Therapeutics
AXSM
$6.05B
| $700K | 0.61% | 6,000 +2,000 | +50% | +$233K |
|
28
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $666K | 0.58% | 30,006 +6 | +0% | +$133 |
|
29
Halozyme
HALO
$8.56B
| $638K | 0.55% | 10,000 | – | – |
|
30
Ultragenyx Pharmaceutical
RARE
$2.89B
| $579K | 0.5% | 16,000 | – | – |
|
31
NovoCure
NVCR
$1.38B
| $552K | 0.48% | 31,000 | – | – |
|
32
Scholar Rock
SRRK
$3.14B
| $514K | 0.45% | 16,000 +8,000 | +100% | +$257K |
|
|
33
OrthoPediatrics
KIDS
$536M
| $493K | 0.43% | +20,000 | New | +$493K |
|
|
34
Solid Biosciences
SLDB
$427M
| $476K | 0.41% | +128,768 | New | +$476K |
|
35
Inhibrx
INBX
$408M
| $449K | 0.39% | 32,110 | – | – |
|
36
10x Genomics
TXG
$1.74B
| $437K | 0.38% | 50,000 | – | – |
|
37
Cytokinetics
CYTK
$4.23B
| $402K | 0.35% | 10,000 | – | – |
|
|
SWTX
38
DELISTED
SpringWorks Therapeutics
SWTX
| $365K | 0.32% | 8,280 -1,720 | -17% | -$75.9K |
|
39
Pulmonx
LUNG
$69.7M
| $343K | 0.3% | 51,000 | – | – |
|
40
Candel Therapeutics
CADL
$318M
| $339K | 0.29% | 60,000 | – | – |
|
41
Alphatec Holdings
ATEC
$2.35B
| $335K | 0.29% | 33,000 -25,000 | -43% | -$254K |
|
42
Wave Life Sciences
WVE
$1.53B
| $326K | 0.28% | 40,300 +300 | +0.8% | +$2.42K |
|
43
MoonLake Immunotherapeutics
MLTX
$3.54B
| $313K | 0.27% | 8,000 +4,000 | +100% | +$156K |
|
44
Apellis Pharmaceuticals
APLS
$3.48B
| $306K | 0.27% | 14,000 | – | – |
|
45
BioCryst Pharmaceuticals
BCRX
$1.74B
| $300K | 0.26% | 40,000 | – | – |
|
46
Apogee Therapeutics
APGE
$2.17B
| $299K | 0.26% | +8,000 | New | +$299K |
|
47
Xencor
XNCR
$580M
| $277K | 0.24% | 26,000 | – | – |
|
|
48
Outset Medical
OM
$247M
| $272K | 0.24% | 24,584 -344,182 | -93% | -$3.81M |
|
|
BPMC
49
DELISTED
Blueprint Medicines
BPMC
| $239K | 0.21% | 2,700 | – | – |
|
50
Amicus Therapeutics
FOLD
$2.34B
| $228K | 0.2% | 28,000 | – | – |
|